Skip to content

Study · Randomized controlled trial · n = 14,752 · 2019

7 results

Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure-Related Outcomes: Insights From the EXSCEL Trial.

Fudim M, White J, Pagidipati NJ, Lokhnygina Y, Wainstein J, Murin J, Iqbal N, Öhman P, Lopes RD, Reicher B, Holman RR, Hernandez AF, Mentz RJ

Circulation23 Sept 2019Cited by 81 (Europe PMC)

PMID31542942 (opens in a new tab)PMCIDPMC6924268 (opens in a new tab)DOI10.1161/circulationaha.119.041659 (opens in a new tab)PepBankPUB-31542942
Source linkPubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In EXSCEL participants with type 2 diabetes, exenatide reduced all-cause death versus placebo.

    In plain wordsIn participants with type 2 diabetes, exenatide reduced all-cause death versus placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseAll-cause death overall
    Study

    n = 14,752

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Mortality · Whole body
    Studied dose
    Dose not stated

    Measurements

    Hazard ratio
    0.86 ratio
    all-cause death

    Source sentences

    Summary
    Overall, those assigned to EQW had a lower incidence of all-cause death (hazard ratio [HR], 0.86 [95% CI, 0.77-0.97]) and the composite outcome of all-cause death or HHF (HR, 0.89 [95% CI, 0.80-0.99]).
    1 context sentence
    Summary · context
    The prespecified analysis of the randomized controlled EXSCEL trial, which enrolled patients with type 2 diabetes mellitus with and without additional cardiovascular disease,
  2. 02HumanRandomized controlled trialEfficacy outcome

    In EXSCEL participants, exenatide reduced all-cause death or heart failure hospitalization versus placebo.

    In plain wordsIn EXSCEL participants, exenatide reduced death or heart failure hospitalization versus placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseAll-cause death or heart failure hospitalization overall
    Study

    n = 14,752

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Hazard ratio
    0.89 ratio
    death or HHF

    Source sentences

    Summary
    Overall, those assigned to EQW had a lower incidence of all-cause death (hazard ratio [HR], 0.86 [95% CI, 0.77-0.97]) and the composite outcome of all-cause death or HHF (HR, 0.89 [95% CI, 0.80-0.99]).
    1 context sentence
    Summary · context
    The prespecified analysis of the randomized controlled EXSCEL trial, which enrolled patients with type 2 diabetes mellitus with and without additional cardiovascular disease,
  3. 03HumanRandomized controlled trialEfficacy outcome

    In EXSCEL participants, exenatide reduced first and recurrent heart failure hospitalizations versus placebo.

    In plain wordsIn EXSCEL participants, exenatide reduced first and recurrent heart failure hospitalizations versus placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseFirst and recurrent heart failure hospitalization
    Study

    n = 14,752

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Hazard ratio
    0.82 ratio
    first plus recurrent HHF

    Source sentences

    Summary
    First, plus recurrent, HHF was reduced in the exenatide group versus placebo (HR, 0.82 [95% CI, 0.68-0.99]; P=0.038).
    1 context sentence
    Summary · context
    The prespecified analysis of the randomized controlled EXSCEL trial, which enrolled patients with type 2 diabetes mellitus with and without additional cardiovascular disease,
  4. 04HumanRandomized controlled trialEfficacy outcome

    In participants with baseline heart failure, exenatide did not reduce all-cause death versus placebo.

    In plain wordsIn participants with baseline heart failure, exenatide did not reduce death versus placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeAll-cause death with baseline heart failure
    Study

    n = 2,389

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Mortality · Whole body
    Studied dose
    Dose not stated

    Measurements

    Hazard ratio
    1.05 ratio
    baseline HF

    Source sentences

    Summary
    When stratified by presence or absence of baseline HF, there was no observed reduction in all-cause death with EQW with baseline HF (HR, 1.05 [95% CI, 0.85-1.29]), while the risk of mortality was reduced with EQW in the no-HF group (HR, 0.79 [95% CI, 0.68-0.92]) with an interaction P value of 0.031.
    1 context sentence
    Summary · context
    The prespecified analysis of the randomized controlled EXSCEL trial, which enrolled patients with type 2 diabetes mellitus with and without additional cardiovascular disease,
  5. 05HumanRandomized controlled trialEfficacy outcome

    In participants with baseline heart failure, exenatide did not reduce death or heart failure hospitalization versus placebo.

    In plain wordsIn participants with baseline heart failure, exenatide did not reduce death or heart failure hospitalization versus placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeDeath or heart failure hospitalization with baseline heart failure
    Study

    n = 2,389

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Hazard ratio
    1.07 ratio
    baseline HF

    Source sentences

    Summary
    The reduction in all-cause death or HHF seen with EQW in patients without baseline HF (HR, 0.81 [95% CI, 0.71-0.93]) was not seen in patients with baseline HF (HR, 1.07 [95% CI, 0.89-1.29]; interaction P=0.015).
    1 context sentence
    Summary · context
    The prespecified analysis of the randomized controlled EXSCEL trial, which enrolled patients with type 2 diabetes mellitus with and without additional cardiovascular disease,
  6. 06HumanRandomized controlled trialEfficacy outcome

    In participants without baseline heart failure, exenatide reduced all-cause death versus placebo.

    In plain wordsIn participants without baseline heart failure, exenatide reduced death versus placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseAll-cause death without baseline heart failure
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Mortality · Whole body
    Studied dose
    Dose not stated

    Measurements

    Hazard ratio
    0.79 ratio
    no baseline HF

    Source sentences

    Summary
    When stratified by presence or absence of baseline HF, there was no observed reduction in all-cause death with EQW with baseline HF (HR, 1.05 [95% CI, 0.85-1.29]), while the risk of mortality was reduced with EQW in the no-HF group (HR, 0.79 [95% CI, 0.68-0.92]) with an interaction P value of 0.031.
    1 context sentence
    Summary · context
    The prespecified analysis of the randomized controlled EXSCEL trial, which enrolled patients with type 2 diabetes mellitus with and without additional cardiovascular disease,
  7. 07HumanRandomized controlled trialEfficacy outcome

    In participants without baseline heart failure, exenatide reduced death or heart failure hospitalization versus placebo.

    In plain wordsIn participants without baseline heart failure, exenatide reduced death or heart failure hospitalization versus placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseDeath or heart failure hospitalization without baseline heart failure
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Hazard ratio
    0.81 ratio
    no baseline HF

    Source sentences

    Summary
    The reduction in all-cause death or HHF seen with EQW in patients without baseline HF (HR, 0.81 [95% CI, 0.71-0.93]) was not seen in patients with baseline HF (HR, 1.07 [95% CI, 0.89-1.29]; interaction P=0.015).
    1 context sentence
    Summary · context
    The prespecified analysis of the randomized controlled EXSCEL trial, which enrolled patients with type 2 diabetes mellitus with and without additional cardiovascular disease,

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01144338

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

AstraZenecan = 14,75218 Jun 2010 to 24 Apr 2017

Type 2 Diabetes Mellitus

Trial pageClinicalTrials.govUpdated 8 Aug 2018

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.